학술논문
Treatment of HCV with ABT-450/r--ombitasvir and dasabuvir with ribavirin
hepatitis C virus
hepatitis C virus
Document Type
Report
Author
Source
The New England Journal of Medicine. April 24, 2014, Vol. 370 Issue 17, p1594, 10 p.
Subject
Language
English
ISSN
0028-4793
Abstract
The study evaluates the safety and efficacy of 12 weeks of an all-oral regimen of ABT-450/r--ombitasvir and dasabuvir with ribavirin in previously untreated patients with hepatitis C virus (HCV) genotype 1 infection and no cirrhosis. Findings indicate that the 12-week multitargeted regimen was highly effective and was associated with a low rate of treatment discontinuation.